NCT03880903

Brief Summary

Acute bronchiolitis is a viral infection that occurs in children most commonly in the first 2 years of life and is characterized by respiratory symptoms, resulting in wheezing and/or crackles upon auscultation. It is usually a self limiting illness. However, this condition may be associated with several severe complications, such as apnea,respiratory failure, or secondary bacterial infection

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
75

participants targeted

Target at P25-P50 for phase_4

Timeline
Completed

Started Jul 2020

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 17, 2019

Completed
2 days until next milestone

First Posted

Study publicly available on registry

March 19, 2019

Completed
1.3 years until next milestone

Study Start

First participant enrolled

July 20, 2020

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 20, 2021

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 20, 2021

Completed
Last Updated

February 11, 2020

Status Verified

March 1, 2019

Enrollment Period

8 months

First QC Date

March 17, 2019

Last Update Submit

February 9, 2020

Conditions

Outcome Measures

Primary Outcomes (1)

  • Hospital length of stay

    time taken to discharge or ready to be discharged

    24 hours

Study Arms (3)

normal saline with bronchdilator

EXPERIMENTAL

will recieve treatment with nebulized brochodilator(salbutamol) and normal saline every 4 to 6 hours

Drug: normal saline and salbutamol

hypertonic saline with bronchodilator

EXPERIMENTAL

will recieve treatment with nebulized bronchodilator(salbutamol) and hypertonic saline every 4 to 6 hours

Drug: hypertonic saline and salbutamol

hypertonic saline only

EXPERIMENTAL

will recieve treatment with nebulized hypertonic saline 3% in adose of 4 ml every 4 to 6 hours

Drug: Hypertonic saline

Interventions

patients will recieve treatment with nebulized salbutamol and normal saline every 4 to 6 in hours

normal saline with bronchdilator

patients will recieve treatment with nebulized salbutamol and hypertonic saline 3% in adose of 4ml every 4 to 6 hours

hypertonic saline with bronchodilator

patients will recieve treatment with nebulized hypertonic saline 3% in adose of 4ml every 4 to 6 hours

hypertonic saline only

Eligibility Criteria

AgeUp to 24 Months
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • infants less than 24 months of age with adiagnosis of acute bronchiolitis

You may not qualify if:

  • other infants and children above 24 months of age
  • patients with other diseases than acute bronchiolitis

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (4)

  • Teshome G, Gattu R, Brown R. Acute bronchiolitis. Pediatr Clin North Am. 2013 Oct;60(5):1019-34. doi: 10.1016/j.pcl.2013.06.005. Epub 2013 Jul 24.

  • Smyth RL, Openshaw PJ. Bronchiolitis. Lancet. 2006 Jul 22;368(9532):312-22. doi: 10.1016/S0140-6736(06)69077-6.

  • Rudan I, Tomaskovic L, Boschi-Pinto C, Campbell H; WHO Child Health Epidemiology Reference Group. Global estimate of the incidence of clinical pneumonia among children under five years of age. Bull World Health Organ. 2004 Dec;82(12):895-903. Epub 2005 Jan 5.

  • Zorc JJ, Hall CB. Bronchiolitis: recent evidence on diagnosis and management. Pediatrics. 2010 Feb;125(2):342-9. doi: 10.1542/peds.2009-2092. Epub 2010 Jan 25.

MeSH Terms

Interventions

Saline SolutionAlbuterolSaline Solution, Hypertonic

Intervention Hierarchy (Ancestors)

Crystalloid SolutionsIsotonic SolutionsSolutionsPharmaceutical PreparationsEthanolaminesAmino AlcoholsAlcoholsOrganic ChemicalsAminesPhenethylaminesEthylaminesHypertonic Solutions

Central Study Contacts

mohamed El Tellawy, professor

CONTACT

Duaa Raafat, Assis prof

CONTACT

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
principle investigator

Study Record Dates

First Submitted

March 17, 2019

First Posted

March 19, 2019

Study Start

July 20, 2020

Primary Completion

March 20, 2021

Study Completion

September 20, 2021

Last Updated

February 11, 2020

Record last verified: 2019-03